Cell therapy in patients with heart failure: a comprehensive review and emerging concepts

Area of Science:

• Regenerative Medicine
• Cardiology
• Cellular Therapy

Background:

• Heart failure (HF) remains a leading cause of morbidity and mortality worldwide.
• Current treatments for HF have limitations, driving the search for novel therapeutic strategies.
• Cell therapy has emerged as a potential regenerative approach for HF patients.

Purpose of the Study:

• To review and summarize the clinical trial evidence for cell therapy in heart failure.
• To evaluate the efficacy and safety of various cell types in HF treatment.
• To identify promising cell types and future directions for cell therapy in HF.

Main Methods:

• Systematic review of Phase I-II clinical trials of cell therapy for heart failure.
• Analysis of efficacy and safety data from studies using different cell types (e.g., mesenchymal stromal cells, cardiosphere-derived cells).
• Evaluation of trial design, endpoints, and long-term outcomes.

Main Results:

• Early-phase trials (Phase I-II) for HF show encouraging results, unlike those for acute myocardial infarction.
• An efficacy signal was observed 6-12 months post-single treatment in both ischemic and non-ischemic cardiomyopathy.
• Mesenchymal stromal cells from various sources show the most promise; embryonic stem cells are unlikely to be viable therapies. No safety concerns have emerged.

Conclusions:

• Cell therapy, particularly with mesenchymal stromal cells, demonstrates potential for treating heart failure.
• The findings support the need for larger, well-designed Phase III trials to establish definitive efficacy.
• Future research should explore optimized delivery methods and allogeneic cell sources for broader clinical application.